法利西单抗治疗新生血管性年龄相关性黄斑变性的早期结果。

IF 0.9 4区医学 Q4 OPHTHALMOLOGY

Ophthalmic surgery, lasers & imaging retina Pub Date : 2025-05-15 DOI:10.3928/23258160-20250304-02

Ferhina S Ali, David C Tabano, Durga S Borkar, Theodore Leng, Vincent Garmo, Ayesha Ahmed, Rachel Myers, Jacqueline K Shaia, Giulio Barteselli, Rishi P Singh

{"title":"法利西单抗治疗新生血管性年龄相关性黄斑变性的早期结果。","authors":"Ferhina S Ali, David C Tabano, Durga S Borkar, Theodore Leng, Vincent Garmo, Ayesha Ahmed, Rachel Myers, Jacqueline K Shaia, Giulio Barteselli, Rishi P Singh","doi":"10.3928/23258160-20250304-02","DOIUrl":null,"url":null,"abstract":"Background and objective: This study assessed treatment patterns and early outcomes among patients with neovascular age-related macular degeneration (nAMD) initiating faricimab in routine clinical practice in the United States.Patients and methods: FARETINA-AMD is a retrospective study among patients with nAMD initiating faricimab from February 2022 to June 2023 identified from the US IRIS® Registry.Results: Included were 21,508 patients previously treated with anti-vascular endothelial growth factor (anti-VEGF) (25,784 eyes) and 1,836 treatment-naïve patients (1,982 eyes) with nAMD. Among previously treated eyes, visual acuity remained stable with faricimab. In treatment-naïve eyes, mean ± SD visual acuity improved from 56.7 ± 24.1 letters at index to 61.4 ± 22.3 after faricimab injection 4 (P < 0.01). Mean ± SD central subfield thickness improved from 315.2 ± 80.0 (index) to 264.9 ± 60.1 μm (injection 4) in treatment-naïve eyes and 296.2 ± 95.5 to 273.0 ± 81.4 μm in previously treated eyes (both P < 0.01).Conclusions: Among patients with nAMD receiving faricimab, visual acuity improved in treatment-naïve eyes, and both previously treated and treatment-naïve eyes experienced anatomical improvement. [Ophthalmic Surg Lasers Imaging Retina 2025;56:XX-XX.].","PeriodicalId":19679,"journal":{"name":"Ophthalmic surgery, lasers & imaging retina","volume":" ","pages":"1-10"},"PeriodicalIF":0.9000,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Early Outcomes After Initiation of Faricimab for Neovascular Age-Related Macular Degeneration.\",\"authors\":\"Ferhina S Ali, David C Tabano, Durga S Borkar, Theodore Leng, Vincent Garmo, Ayesha Ahmed, Rachel Myers, Jacqueline K Shaia, Giulio Barteselli, Rishi P Singh\",\"doi\":\"10.3928/23258160-20250304-02\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background and objective: This study assessed treatment patterns and early outcomes among patients with neovascular age-related macular degeneration (nAMD) initiating faricimab in routine clinical practice in the United States.Patients and methods: FARETINA-AMD is a retrospective study among patients with nAMD initiating faricimab from February 2022 to June 2023 identified from the US IRIS® Registry.Results: Included were 21,508 patients previously treated with anti-vascular endothelial growth factor (anti-VEGF) (25,784 eyes) and 1,836 treatment-naïve patients (1,982 eyes) with nAMD. Among previously treated eyes, visual acuity remained stable with faricimab. In treatment-naïve eyes, mean ± SD visual acuity improved from 56.7 ± 24.1 letters at index to 61.4 ± 22.3 after faricimab injection 4 (P < 0.01). Mean ± SD central subfield thickness improved from 315.2 ± 80.0 (index) to 264.9 ± 60.1 μm (injection 4) in treatment-naïve eyes and 296.2 ± 95.5 to 273.0 ± 81.4 μm in previously treated eyes (both P < 0.01).Conclusions: Among patients with nAMD receiving faricimab, visual acuity improved in treatment-naïve eyes, and both previously treated and treatment-naïve eyes experienced anatomical improvement. [Ophthalmic Surg Lasers Imaging Retina 2025;56:XX-XX.].\",\"PeriodicalId\":19679,\"journal\":{\"name\":\"Ophthalmic surgery, lasers & imaging retina\",\"volume\":\" \",\"pages\":\"1-10\"},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2025-05-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ophthalmic surgery, lasers & imaging retina\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3928/23258160-20250304-02\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmic surgery, lasers & imaging retina","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3928/23258160-20250304-02","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景和目的：本研究评估了美国新生血管性年龄相关性黄斑变性（nAMD）患者在常规临床实践中开始使用法昔单抗的治疗模式和早期结果。患者和方法：FARETINA-AMD是一项回顾性研究，研究对象为2022年2月至2023年6月期间开始使用faricimab的nAMD患者，这些患者来自美国IRIS®注册中心。结果：纳入21,508例先前接受抗血管内皮生长因子（anti-VEGF）治疗的患者（25,784眼）和1,836例treatment-naïve患者（1,982眼）。在先前治疗过的眼睛中，faricimab的视力保持稳定。treatment-naïve眼的平均±SD视力由56.7±24.1个字母提高到61.4±22.3个字母（P < 0.01）。treatment-naïve组中心子野厚度均值±SD由315.2±80.0 μm（指数）提高到264.9±60.1 μm（注射4），对照组由296.2±95.5 μm提高到273.0±81.4 μm （P均< 0.01）。结论：在接受faricimab治疗的nAMD患者中，treatment-naïve眼的视力得到改善，并且既往治疗和treatment-naïve眼的解剖结构都得到改善。[眼科外科激光成像视网膜2025；56:XX-XX]。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Early Outcomes After Initiation of Faricimab for Neovascular Age-Related Macular Degeneration.

Background and objective: This study assessed treatment patterns and early outcomes among patients with neovascular age-related macular degeneration (nAMD) initiating faricimab in routine clinical practice in the United States.

Patients and methods: FARETINA-AMD is a retrospective study among patients with nAMD initiating faricimab from February 2022 to June 2023 identified from the US IRIS^® Registry.

Results: Included were 21,508 patients previously treated with anti-vascular endothelial growth factor (anti-VEGF) (25,784 eyes) and 1,836 treatment-naïve patients (1,982 eyes) with nAMD. Among previously treated eyes, visual acuity remained stable with faricimab. In treatment-naïve eyes, mean ± SD visual acuity improved from 56.7 ± 24.1 letters at index to 61.4 ± 22.3 after faricimab injection 4 (P < 0.01). Mean ± SD central subfield thickness improved from 315.2 ± 80.0 (index) to 264.9 ± 60.1 μm (injection 4) in treatment-naïve eyes and 296.2 ± 95.5 to 273.0 ± 81.4 μm in previously treated eyes (both P < 0.01).

Conclusions: Among patients with nAMD receiving faricimab, visual acuity improved in treatment-naïve eyes, and both previously treated and treatment-naïve eyes experienced anatomical improvement. [Ophthalmic Surg Lasers Imaging Retina 2025;56:XX-XX.].

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Ophthalmic surgery, lasers & imaging retina OPHTHALMOLOGY-SURGERY

CiteScore

1.80

自引率

0.00%

发文量

期刊介绍： OSLI Retina focuses exclusively on retinal diseases, surgery and pharmacotherapy. OSLI Retina will offer an expedited submission to publication effort of peer-reviewed clinical science and case report articles. The front of the journal offers practical clinical and practice management features and columns specific to retina specialists. In sum, readers will find important peer-reviewed retina articles and the latest findings in techniques and science, as well as informative business and practice management features in one journal.